2024
Acute exacerbations in patients with progressive pulmonary fibrosis
Kreuter M, Belloli E, Bendstrup E, Cerri S, Flaherty K, Shapera S, Song J, Mueller H, Rohr K, Kondoh Y, investigators O, Quadrelli S, Otaola M, Bergna M, Elias P, Arce G, Cazaux A, Guiot J, Bondue B, Dahlqvist C, Homik L, Shapera S, Cantin A, Kolb M, Fénero M, Rozas R, Orellana A, Xu Z, Luo Q, Kang J, Cai H, Marchand-Adam S, Bergot E, Gamez-Dubuis A, Riviere F, Kessler R, Nunes H, Marquette C, Wemeau L, Jouneau S, Lebargy F, Crestani B, Cottin V, Reynaud-Gaubert M, Blaas S, Bonella F, Randerath W, Hetzel J, Koschel D, Kreuter M, Prasse A, Skowasch D, Stieglitz S, Refini R, Cerri S, Pesci A, Tomassetti S, Vancheri C, Varone F, Sakamoto N, Abe S, Hayashi H, Saito T, Suda T, Kitamura H, Okamoto M, Kondoh Y, Makino S, Takeuchi T, Yamada Y, Kono C, Inoue Y, Sugiura H, Kishi K, Takaya H, Yamauchi H, Ichikado K, Tomii K, Takahashi H, Izumi S, Kawamura T, Nishioka Y, Miyazaki Y, Song J, Park J, Kim Y, Jassem E, Kus J, Piotrowski W, Barczyk A, Ziora D, Bazdyrev E, Moiseev S, Avdeev S, Ilkovich M, Yakusevich V, Valenzuela C, Acosta O, Martínez M, Gómez L, Molina-Molina M, Villegas D, Aburto M, Portal J, Villar A, Jiménez A, Sauleda J, Arias M, Beirne P, Stone H, Hope-Gill B, Hirani N, Chaudhuri N, Gifford A, Jones L, Morrison L, Antin-Ozerkis D, Bhatt N, Kulkarni T, Moua T, Ettinger N, Pitts L, Veeraraghavan S, Padilla M, Pérez E, Giessel G, Strek M, Danoff S, Burk J, Rossman M, Patel N, Belloli E, Hotchkin D, Weigt S, Scholand M, Kaner R, Sigal B, Safdar Z, Tolle L, Martinez R, Glassberg M, Hallowell R, Golden J, Schwartz M, Britt E, Morrow L, Mageto Y, Buch K, Chaaban S, Poonyagariyagorn H, Dilling D, Shlobin O, Thavarajah K, Nambiar A, Rosas I, Bascom R, Oldham J, Schmidt S, D'Amico J, Falk J, Glazer C, Criner G. Acute exacerbations in patients with progressive pulmonary fibrosis. ERJ Open Research 2024, 10: 00403-2024. PMID: 39624387, PMCID: PMC11610068, DOI: 10.1183/23120541.00403-2024.Peer-Reviewed Original ResearchProgressive pulmonary fibrosisInterstitial lung diseaseIdiopathic pulmonary fibrosisAcute exacerbationPulmonary fibrosisAcute exacerbation of idiopathic pulmonary fibrosisExacerbation of idiopathic pulmonary fibrosisHazard ratioFibrosing ILDsProgressive fibrosing ILDsRisk factorsRisk of acute exacerbationIncreased risk of acute exacerbationAssociated with high mortalityMedian follow-upKaplan-Meier methodCox proportional hazards modelsInvestigate risk factorsRisk of deathProportional hazards modelRisk factor analysisPrognostic impactINBUILD trialBaseline characteristicsFollow-up
2020
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
Wells A, Flaherty K, Brown K, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts W, Stowasser S, Quaresma M, Goeldner R, Schlenker-Herceg R, Kolb M, investigators I, Abe S, Aburto M, Acosta O, Andrews C, Antin-Ozerkis D, Arce G, Arias M, Avdeev S, Barczyk A, Bascom R, Bazdyrev E, Beirne P, Belloli E, Bergna M, Bergot E, Bhatt N, Blaas S, Bondue B, Bonella F, Britt E, Buch K, Burk J, Cai H, Cantin A, Villegas D, Cazaux A, Cerri S, Chaaban S, Chaudhuri N, Cottin V, Crestani B, Criner G, Dahlqvist C, Danoff S, D'Amico J, Dilling D, Elias P, Ettinger N, Falk J, Pérez E, Gamez-Dubuis A, Giessel G, Gifford A, Glassberg M, Glazer C, Golden J, Carrera L, Guiot J, Hallowell R, Hayashi H, Hetzel J, Hirani N, Homik L, Hope-Gill B, Hotchkin D, Ichikado K, Ilkovich M, Inoue Y, Izumi S, Jassem E, Jones L, Jouneau S, Kaner R, Kang J, Kawamura T, Kessler R, Kim Y, Kishi K, Kitamura H, Kolb M, Kondoh Y, Kono C, Koschel D, Kreuter M, Kulkarni T, Kus J, Lebargy F, Jiménez A, Luo Q, Mageto Y, Maher T, Makino S, Marchand-Adam S, Marquette C, Martinez R, Martínez M, Rozas R, Miyazaki Y, Moiseev S, Molina-Molina M, Morrison L, Morrow L, Moua T, Nambiar A, Nishioka Y, Nunes H, Okamoto M, Oldham J, Otaola M, Padilla M, Park J, Patel N, Pesci A, Piotrowski W, Pitts L, Poonyagariyagorn H, Prasse A, Quadrelli S, Randerath W, Refini R, Reynaud-Gaubert M, Riviere F, Portal J, Rosas I, Rossman M, Safdar Z, Saito T, Sakamoto N, Fénero M, Sauleda J, Schmidt S, Scholand M, Schwartz M, Shapera S, Shlobin O, Sigal B, Orellana A, Skowasch D, Song J, Stieglitz S, Stone H, Strek M, Suda T, Sugiura H, Takahashi H, Takaya H, Takeuchi T, Thavarajah K, Tolle L, Tomassetti S, Tomii K, Valenzuela C, Vancheri C, Varone F, Veeraraghavan S, Villar A, Weigt S, Wemeau L, Wuyts W, Xu Z, Yakusevich V, Yamada Y, Yamauchi H, Ziora D. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. The Lancet Respiratory Medicine 2020, 8: 453-460. PMID: 32145830, DOI: 10.1016/s2213-2600(20)30036-9.Peer-Reviewed Original ResearchConceptsInterstitial lung diseaseIdiopathic pulmonary fibrosisIdiopathic non-specific interstitial pneumoniaAutoimmune interstitial lung diseaseUnclassifiable idiopathic interstitial pneumoniaNon-specific interstitial pneumoniaDose of nintedanibParallel-group trialIdiopathic interstitial pneumoniaEffect of nintedanibINBUILD trialInterstitial pneumoniaILD diagnosisHigh-resolution CTILD progressionFVC declineHypersensitivity pneumonitisProgressive fibrosing interstitial lung diseasesOverall populationInterstitial lung disease diagnosisChest imaging featuresProtocol-defined criteriaSafety of nintedanibChronic hypersensitivity pneumonitisDisease subgroup analyses